{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:45:24Z","timestamp":1776408324305,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00192-021-04970-0","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T09:02:31Z","timestamp":1631264551000},"page":"2891-2897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pentosan associated retinal pigmentary changes: FDA\u2019s perspective on an emerging postmarketing safety finding"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-545X","authenticated-orcid":false,"given":"Allison","family":"Lardieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Konkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"McCulley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Moeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiley","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebola","family":"Ajao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"11","key":"4970_CR1","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ophtha.2018.04.026","volume":"125","author":"WA Pearce","year":"2018","unstructured":"Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology. 2018;125(11):1793\u2013802. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.026.","journal-title":"Ophthalmology."},{"issue":"7","key":"4970_CR2","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2018.12.037","volume":"126","author":"T Greenlee","year":"2019","unstructured":"Greenlee T, Hom G, Conti T, Babiuch AS, Singh R. Re: Pearce et al.: Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium (Ophthalmology. 2018;125:1793-1802). Ophthalmology. 2019;126(7):e51. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.037.","journal-title":"Ophthalmology"},{"issue":"11","key":"4970_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaophthalmol.2019.3392","volume":"137","author":"AM Hanif","year":"2019","unstructured":"Hanif AM, Armenti ST, Taylor SC, Shah RA, Igelman AD, Jayasundera KT, Pennesi ME, Khurana RN, Foote JE, O'Keefe GA, Yang P, Hubbard GB 3rd, Hwang TS, Flaxel CJ, Stein JD, Yan J, Jain N. Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study. JAMA Ophthalmol. 2019;137(11):1275\u201382. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3392.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"4970_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3928\/23258160-20191009-10","volume":"50","author":"RM Huckfeldt","year":"2019","unstructured":"Huckfeldt RM, Vavvas DG. Progressive maculopathy after discontinuation of pentosan polysulfate sodium. Ophthalmic Surg Lasers Imaging Retina. 2019;50(10):656\u20139. https:\/\/doi.org\/10.3928\/23258160-20191009-10.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"4970_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.oret.2019.08.006","volume":"4","author":"K Mishra","year":"2020","unstructured":"Mishra K, Patel TP, Singh MS. Choroidal neovascularization associated with pentosan polysulfate toxicity. Ophthalmol Retina. 2020;4(1):111\u20133. https:\/\/doi.org\/10.1016\/j.oret.2019.08.006.","journal-title":"Ophthalmol Retina"},{"key":"4970_CR6","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.ajoc.2020.100604","volume":"17","author":"RA Vora","year":"2020","unstructured":"Vora RA, Patel AP, Yang SS, Melles R. A case of pentosan polysulfate maculopathy originally diagnosed as stargardt disease. Am J Ophthalmol Case Rep. 2020;17:100604. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100604.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"4970_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ophtha.2019.10.013","volume":"127","author":"A Hadad","year":"2020","unstructured":"Hadad A, Helmy O, Leeman S, Schaal S. A novel multimethod image analysis to quantify pentosan polysulfate sodium retinal toxicity. Ophthalmology. 2020 Mar;127(3):429\u201331. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.013.","journal-title":"Ophthalmology."},{"issue":"10","key":"4970_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ophtha.2019.04.024","volume":"126","author":"AM Hanif","year":"2019","unstructured":"Hanif AM, Shah R, Yan J, Varghese JS, Patel SA, Cribbs BE, O'Keefe G, Hendrick AM, Shantha JG, Hubbard GB 3rd, Patel PS, Rao P, Yeh S, Jain N. Strength of association between pentosan polysulfate and a novel maculopathy. Ophthalmology. 2019 Oct;126(10):1464\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.024.","journal-title":"Ophthalmology"},{"key":"4970_CR9","unstructured":"Vander Beek BL, Li AL, Yu Y, Jain N. Association of macular disease with use of pentosan polysulfate sodium. Pharmacoepidemiology and Drug Safety. 2019;28 Supplement 2(343) [Abstract only]."},{"key":"4970_CR10","doi-asserted-by":"publisher","unstructured":"Ludwig CA, Vail D, Callaway NF, Pasricha MV, Moshfeghi DM. Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States. Ophthalmology. 2019. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.036.","DOI":"10.1016\/j.ophtha.2019.10.036"},{"key":"4970_CR11","doi-asserted-by":"publisher","unstructured":"Wang D, Au A, Gunnemann F, Hilely A, Scharf J, Tran K, Sun M, Kim JH, Sarraf D. Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. Can J Ophthalmol. 2020. https:\/\/doi.org\/10.1016\/j.jcjo.2019.12.001.","DOI":"10.1016\/j.jcjo.2019.12.001"},{"issue":"6","key":"4970_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ophtha.2020.01.017","volume":"127","author":"RA Vora","year":"2020","unstructured":"Vora RA, Patel AP, Melles R. Prevalence of maculopathy associated with long-term pentosan polysulfate therapy. Ophthalmology. 2020 Jun;127(6):835\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.017.","journal-title":"Ophthalmology."},{"key":"4970_CR13","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.urology.2020.04.006","volume":"141","author":"MJ Wingelaar","year":"2020","unstructured":"Wingelaar MJ, Raevis JJ, Conlin KA, Stepien KE. Retinal toxicity in a patient on pentosan polysulfate sodium. Urology. 2020 Jul;141:e41\u20132. https:\/\/doi.org\/10.1016\/j.urology.2020.04.006.","journal-title":"Urology."},{"key":"4970_CR14","unstructured":"Hanno PM, Burks DA, Clemens JQ et al. Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome. American Urological Association (AUA) Guideline. 2014."},{"issue":"3","key":"4970_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","volume":"170","author":"GR Sant","year":"2003","unstructured":"Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW. Nyberg LM; interstitial cystitis clinical trials group. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810\u20135. https:\/\/doi.org\/10.1097\/01.ju.0000083020.06212.3d.","journal-title":"J Urol"},{"issue":"6","key":"4970_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/0090-4295(90)80116-5","volume":"35","author":"SG Mulholland","year":"1990","unstructured":"Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology. 1990 Jun;35(6):552\u20138. https:\/\/doi.org\/10.1016\/0090-4295(90)80116-5.","journal-title":"Urology"},{"issue":"3","key":"4970_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/s0022-5347(17)35629-x","volume":"150","author":"CL Parsons","year":"1993","unstructured":"Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosan polysulfate. J Urol. 1993 Sep;150(3):845\u20138. https:\/\/doi.org\/10.1016\/s0022-5347(17)35629-x.","journal-title":"J Urol"},{"key":"4970_CR18","unstructured":"Elmiron (pentosan polysulfate sodium) [package insert]. Janssen Pharmaceuticals, Inc. Titusville, New Jersey. September 2018."},{"issue":"8","key":"4970_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/bjophthalmol-2019-314765","volume":"104","author":"N Jain","year":"2020","unstructured":"Jain N, Li AL, Yu Y, VanderBeek BL. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol. 2020;104(8):1093\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314765.","journal-title":"Br J Ophthalmol."},{"key":"4970_CR20","unstructured":"Elmiron (pentosan polysulfate sodium) [package insert]. Janssen Pharmaceuticals, Inc. Titusville, New Jersey. June 2020."}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04970-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-021-04970-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-021-04970-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:25:30Z","timestamp":1634916330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-021-04970-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4970"],"URL":"https:\/\/doi.org\/10.1007\/s00192-021-04970-0","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"7 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclaimer\/conflict of interest"}},{"value":"The authors have no potential conflicts of interest and nothing to disclose. The views expressed are those of the authors and do not necessarily represent the position of the US FDA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}]}}